RxDoctor Payments Data

Stephen Doucet, MD

Family Medicine · Houston, TXNPI 1235635376

Payments from drug & device makers

$721in general payments, 2019–2025

Across 27 payments — averaging $26.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$219
  • Novo Nordisk$143
  • Sanofi US Services Inc.$76
  • Merck$63
  • Medtronic$43
  • Electromed, Inc.$27
  • plus $150 from 7 others

What the payments were for

  • Food & beverage$721100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$721 in reported general payments places this provider in the 55th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$82,089
Medicare patients
278
Services billed
829

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide117$143,985
EliquisApixaban88$68,397
JardianceEmpagliflozin22$29,913
XareltoRivaroxaban17$27,795
FarxigaDapagliflozin Propanediol23$24,709
Cromolyn Sodium59$18,451
MyrbetriqMirabegron28$15,394
Repatha SureclickEvolocumab15$11,091
Spiriva HandihalerTiotropium Bromide12$10,579
JanumetSitagliptin Phos/Metformin Hcl14$8,777
BelsomraSuvorexant18$8,038
EntrestoSacubitril/Valsartan20$6,814
Fluticasone-SalmeterolFluticasone Propion/Salmeterol21$3,290
Advair DiskusFluticasone Propion/Salmeterol12$3,195
Pregabalin166$3,177

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$219$143,985117 claims
MerckJanumet, Belsomra$63$16,81532 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →